Jefferies Financial Group Inc. Purchases 3,864,636 Shares of Immatics N.V. $IMTX

Jefferies Financial Group Inc. lifted its position in Immatics N.V. (NASDAQ:IMTX) by 323.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 5,059,551 shares of the company’s stock after purchasing an additional 3,864,636 shares during the quarter. Jefferies Financial Group Inc.’s holdings in Immatics were worth $53,125,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. Baker BROS. Advisors LP grew its holdings in shares of Immatics by 18.9% in the 3rd quarter. Baker BROS. Advisors LP now owns 12,094,094 shares of the company’s stock worth $103,042,000 after purchasing an additional 1,925,193 shares during the last quarter. Vestal Point Capital LP grew its holdings in shares of Immatics by 1.6% in the 3rd quarter. Vestal Point Capital LP now owns 6,350,000 shares of the company’s stock worth $54,102,000 after purchasing an additional 100,000 shares during the last quarter. Sofinnova Investments Inc. grew its holdings in shares of Immatics by 44.1% in the 2nd quarter. Sofinnova Investments Inc. now owns 2,240,528 shares of the company’s stock worth $12,054,000 after purchasing an additional 686,224 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Immatics by 9.7% in the 3rd quarter. Aberdeen Group plc now owns 789,446 shares of the company’s stock worth $6,726,000 after purchasing an additional 69,860 shares during the last quarter. Finally, Wasatch Advisors LP grew its holdings in shares of Immatics by 35.9% in the 2nd quarter. Wasatch Advisors LP now owns 785,154 shares of the company’s stock worth $4,224,000 after purchasing an additional 207,491 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

Immatics Stock Up 5.1%

Shares of NASDAQ:IMTX opened at $11.62 on Friday. Immatics N.V. has a 12 month low of $4.93 and a 12 month high of $12.41. The company’s 50-day moving average price is $10.58 and its two-hundred day moving average price is $10.19. The firm has a market cap of $1.56 billion, a P/E ratio of -5.84 and a beta of 1.31.

Immatics (NASDAQ:IMTX) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.08). Immatics had a negative return on equity of 47.36% and a negative net margin of 572.35%.The company had revenue of $8.81 million for the quarter, compared to the consensus estimate of $9.79 million. As a group, equities analysts predict that Immatics N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IMTX shares. Wall Street Zen lowered shares of Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Mizuho set a $25.00 target price on shares of Immatics in a report on Thursday, February 19th. Chardan Capital reaffirmed a “buy” rating and issued a $25.00 target price on shares of Immatics in a report on Tuesday, May 19th. TD Cowen began coverage on shares of Immatics in a report on Tuesday, April 28th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group began coverage on shares of Immatics in a report on Monday, March 16th. They set a “buy” rating and a $18.00 price objective on the stock. Seven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $19.00.

Immatics Company Profile

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.